Search

Shelter-in-place orders to reduce the spread of COVID-19 put unusual strains on people with obesity

Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells.

A program that asks patients to mail in stool samples to screen for colon cancer is an effective way to expand screenings to underserved and underinsured communities and offers an alternative to in-person testing during the pandemic, according to a study conducted by UT Southwestern.

Email Address (you@someplace.com) *Required × Error: A field is missing data or special characters were used. Please correct. Recipient Email Address (recipient@someplace.com) *Required × Error: A field is missing data or special characters were used. Please correct. × Error: A field is missing data or special characters were used. Please correct. Optional Message × Error: A field is missing data or special characters were used. Please correct. Yes! Send me news from UT Southwestern Medical

UT Southwestern Communications tells stories about the extraordinary work being done here every day and about the dedicated, passionate people behind it. Explore these stories.

UT Southwestern Medical Center has received an award from the Advanced Research Projects Agency for Health (ARPA-H) to develop livers using patients’ own cells and an innovative three-dimensional (3D) printing approach.

A once-daily combination treatment for those with uncontrolled Type 2 diabetes amplifies the treatment’s effects – lowering both weight and the number of hypoglycemic events, and improving quality of life and glucose control ¬– and makes participants more likely to adhere to their medications.

When Haley and Zachary Sanders had their first baby, Rowan, and learned she had multiple heart defects, they were shattered. They never imagined technology borrowed from video games would help save their baby’s life.

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some cases.

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.